2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
14
Carcinoid Tumor
5
Gastro-enteropancreatic neuroendocrine tumor
4
Acromegaly
4
Serotonin Syndrome
2
Pituitary Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Hepatocellular
2
Prostatic Neoplasms
1
Pheochromocytoma
1
Peritoneal Neoplasms
1
Paraganglioma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors in Lung
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Intestinal Obstruction
1
Growth Hormone-Secreting Pituitary Adenoma
1
Gigantism
1
Gastrointestinal Neoplasms
1
Flushing
1
Endocrine Tumors
1
Diarrhea
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Carcinoid Heart Disease
1
Adenoma, Islet Cell
1
Interventions
Octreotide
6
Irinotecan
6
Loperamide
5
Probiotics
3
Leucovorin
3
Fluorouracil
3
Fecal Microbiota Transplantation
3
Calcium Aluminosilicate
3
maltodextrin
2
telotristat ethyl
1
shosaiko-to
1
lanreotide
1
isatuximab
1
ceterizine hydrochloride
1
capivasertib
1
cabazitaxel
1
bile acid binding proteins
1
XRP6258
1
Theophylline
1
Temozolomide
1
Surveys and Questionnaires
1
Sulfasalazine
1
Sugars
1
Standard of Care
1
Raloxifene Hydrochloride
1
Radiation
1
Prednisone
1
PHY 906
1
Oxaliplatin
1
Long-Term Synaptic Depression
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diarrhea
×
lanreotide
×
Clear all
NCT00774930
2022-10-14
ELECT
Ipsen
Phase 3
Completed
115 enrolled
17 charts